HIV Therapy: The Latest Developments in Antiviral Drugs
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 1136
Special Issue Editor
Interests: HIV; infectious diseases; COPD
Special Issue Information
Dear Colleagues,
This Special Issue, "HIV Therapy: The Latest Developments in Antiviral Drugs", aims to collate cutting-edge experimental and laboratory research on HIV treatments. Despite significant advancements in antiretroviral therapy (ART), challenges such as drug resistance, long-term toxicity, and the quest for a functional cure or eradication necessitate continuous innovation.
We invite contributions that delve into novel antiviral agents, including small molecules and biologics; their mechanisms of action; and innovative therapeutic strategies. Emphasis will be placed on preclinical studies, in vitro and ex vivo models, the virological and immunological mechanisms underlying new therapies, novel drug delivery systems explored at the laboratory level, and approaches to understanding and targeting HIV reservoirs.
This Special Issue will highlight basic and translational research that underpins the development of next-generation HIV therapies, focusing on the molecular, cellular, and immunological insights that will pave the way for future clinical applications. We welcome original research articles and comprehensive reviews that fit within this experimental medicine framework.
Dr. Francisco Javier Fanjul Losa
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HIV
- antiviral drugs
- experimental therapeutics
- drug discovery
- viral reservoirs
- mechanism of action
- preclinical models
- novel HIV targets
- antiretroviral therapy (ART)
- immunotherapy (experimental aspects)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
